https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
Costs and outcomes were discounted (3%/year). Higher cost/patient (€177,618 vs €151,434) and greater QALYs (5,70 vs 4,62) were obtained with GO+SOC vs SOC. The ICUR was €24,203/QALY gained. This simulation suggests that GO + SOC could be a cost-effective option for treatment of patients with AML in first line. This simulation suggests that GO + SOC could be a cost-effective option for treatment of patients with de novo AML in first line. Bacterial urinary tract infection (BUTI) is the commonest urinary tract infection among
Like
Comment
Share
